A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study

European Urology

Volumn 63, Issue 5, 2013, Pages 927-935

  Klotz, Laurence H ^a   McNeill, Irene Y ^a   Kebabdjian, Marlene ^a   Zhang, Liying ^a   Chin, Joseph L ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Androgen deprivation therapy; Bisphosphonates; Bone health; Bone mineral density; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 1; LEUPRORELIN; PLACEBO; TELOPEPTIDE; VITAMIN D;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; HEART DISEASE; HEMATURIA; HIP; HOT FLUSH; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; LEG EDEMA; LETHARGY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NEOPLASM; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CROSS LINKING; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SPINE; SWELLING; TOOTH FRACTURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; WEAKNESS;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CANADA; CHI-SQUARE DISTRIBUTION; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HIP JOINT; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUPROLIDE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT SELECTION; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876048861     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.09.007     Document Type: Article

References (28)

1. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
2. T.L. Krupski, M.R. Smith, and W.C. Lee Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy Cancer 101 2004 541 549
3. M.F. Townsend, W.H. Sanders, R.O. Northway, and S.D. Graham Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma Cancer 79 1997 545 550
4. T. Hatano, Y. Oishi, A. Furuta, S. Iwamuro, and K. Tashiro Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer BJU Int 86 2000 449 452
5. M.G. Oefelein, V. Ricchuiti, and W. Conrad Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer J Urol 166 2001 1724 1728
6. S.A. Stoch, R.A. Parker, and L. Chen Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists J Clin Endocrinol Metab 86 2001 2787 2791
7. H.W. Daniell Osteoporosis after orchiectomy for prostate cancer J Urol 157 1997 439 444
8. J.T. Wei, M. Gross, and C.A. Jaffe Androgen deprivation therapy for prostate cancer results in significant loss of bone density Urology 54 1999 607 611
9. B.J. Kiratli, S. Srinivas, I. Perkash, and M.K. Terris Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer Urology 57 2001 127 132
10. A. Berruti, L. Dogliotti, and C. Terrone Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy J Urol 167 2002 2361 2367 discussion 2367
11. Y.K. Lau, E. Lee, H.J. Prior, L.M. Lix, C.J. Metge, and W.D. Leslie Fracture risk in androgen deprivation therapy: a Canadian population based analysis Can J Urol 16 2009 4908 4914
12. S.L. Greenspan, P. Coates, S.M. Sereika, J.B. Nelson, D.L. Trump, and N.M. Resnick Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer J Clin Endocrinol Metab 90 2005 6410 6417
13. V. Dhanapal, and D.J. Reeves Bone health management in prostate cancer patients receiving androgen deprivation therapy J Oncol Pharm Pract 18 2012 84 90
14. B. Dawson-Hughes, S.S. Harris, E.A. Drall, and D.E. Dallal Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 1997 670 676
15. E.F.T. Yee, R.E. White, G.H. Murata, C. Handanos, and R.M. Hoffman Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy Gen Intern Med 22 2007 1305 1310
16. M.R. Smith, J. Eastham, D.M. Gleason, D. Shasha, S. Tchekmedyian, and N. Zinner Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
17. T.H. Diamond, J. Winters, and A. Smith The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study Cancer 92 2001 1444 1450
18. M.R. Smith, F.J. McGovern, and A.L. Zietman Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
19. S.L. Greenspan, J.B. Nelson, D.L. Trump, and M. Resnick Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann Intern Med 146 2007 416 424
20. S.L. Greenspan, J.B. Nelson, and D.L. Trump Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy J Clin Oncol 26 2008 4426 4434
21. J. Planas, E. Trilla, and C. Raventos Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy with severe osteopenia or osteoporosis BJU Int 104 2009 1637 1640
22. M.R. Smith, B. Egerdie, N. Hernández Toriz Denosumab HALT Prostate Cancer Study Group Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
23. P.J. Saylor, R.A. Morton, M.L. Hancock, K.G. Barnette, M.S. Steiner, and M.R. Smith Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer J Urol 186 2011 482 486
24. Dietary supplement fact sheet: vitamin D. National Institutes of Health, Office of Dietary Supplements Web site. http://ods.od.nih.gov/factsheets/ vitamind.
25. Vitamin D and calcium: updated dietary reference intakes. Health Canada Web site. http://www.hc-sc.gc.ca/fn-an/nutrition/vitamin/vita-d-eng.php.
26. P. Garnero, E. Hausherr, and M.C. Chapuy Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study J Bone Miner Res 11 1996 1531 1538
27. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
28. P.J. Saylor, and M.R. Smith Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer Natl Compr Canc Netw 8 2010 211 223